Efficacy and Safety of Sirolimus (mTOR Inhibitor) in Two Patients with Diazoxide-Unresponsive Hyperinsulinemic Hypoglycemia

Cengiz Kara1, Gülay Can Yılmaz1, Hüseyin Demirbilek2, Sarah E. Flanagan3, Sian Ellard2, Khalid Hussain4, Murat Aydın1

1Ondokuz Mayıs University Faculty of Medicine, Department of Pediatric Endocrinology, Samsun, Turkey
2Hacettepe University Faculty of Medicine, Department of Pediatric Endocrinology, Ankara, Turkey
3University of Exeter Medical School, Institute of Biomedical and Clinical Science, Exeter, UK
4University College London Institute of Child Health, Department of Pediatric Endocrinology, London, UK

Although sirolimus is a novel treatment option for congenital hyperinsulinism (CHI), which often requires surgery, its immune suppressive and toxic side effects may limit its usage. We present the efficacy and safety of sirolimus in two patients with diazoxide-unresponsive CHI.

Case 1: A male presented at the first postnatal day with hypoglycemic convulsions and a diagnosis of CHI was confirmed. Genetic analysis identified two homozygous mutations, p.L270M and p.E288K in the ABCC8 gene. Despite maximum doses of diazoxide, octreotide, and glucagon, the requirement of 18 mg/kg/min glucose infusion suggested medically unresponsive CHI. At postnatal day 15, sirolimus was commenced at a dose of 0.5 mg/m2/day which was gradually increased and glucose infusion was tapered accordingly. Blood sirolimus level of 27.9 ng/mL (N: 5-15 ng/mL) was attained at a dose of 2 mg/m2/day and normoglycemia was achieved with no need for treatment. The patient however developed renal and hepatic failure which recovered spontaneously following withdrawal of sirolimus. When sirolimus level dropped to therapeutic range, hypoglycemia episodes recurred. He also had three episodes of blood culture-confirmed sepsis. He was referred to another center for surgery.

Case 2: A 5-year-old male was admitted with a history of CHI diagnosed at postnatal day 45 having previous partial (80%) pancreatectomy. Following the identification of homozygous p.R1494W mutation in the ABCC8 gene, diazoxide was stopped and sirolimus was commenced. Dose was gradually increased to 1.0 mg/m2/day and the patient showed a good glycemnic response. Octreotide dose was reduced from 20 μg/kg/day to 6.6 μg/kg/day with no hypoglycemia episode and excellent fasting tolerance up to 10 hours. Except for mild elevation of liver enzymes, no side effects were observed. In conclusion, we present two distinct experiences on the efficacy and safety of sirolimus. These findings suggest a comprehensive need for identifying the optimal doses and therapeutic blood level in addition to careful monitoring for side effects.

Key words: Congenital hyperinsulinism, diazoxide, sirolimus, immunosuppression, toxic side effects

Successful Transfer from Insulin to Oral Sulphonylurea in an Infant and His Mother with Monogenic Diabetes Due to a Heterozygous Missense Mutation in the ABCC8 Gene

Mehmet Nuri Özbek1, Hüseyin Demirbilek2, Sibel Tannirverdi3, Ved Bhushan Arya4, Sarah E. Flanagan5, Sian Ellard5, Khalid Hussain4

1Diyarbakir Research and Training Hospital, Clinic of Pediatric Endocrinology, Diyarbakir, Turkey
2Hacettepe University Faculty of Medicine, Department of Pediatric Endocrinology, Ankara, Turkey
3Diyarbakir Research and Training Hospital, Clinic of Pediatrics, Diyarbakir, Turkey
4Great Ormond Street Hospital for Children, Clinic of Pediatric Endocrinology, London, UK
5University of Exeter Medical School, Institute of Biomedical and Clinical Science, Exeter, UK

Neonatal diabetes mellitus (NDM) which can be transient of permanent is a rare form of monogenic diabetes which usually presents in the first 6 months of life. Mutations in the KATP channel genes (ABCC8 and KCNJ11) are the most common cause of NDM. NDM due to ABCC8 and KCNJ11 mutations can be sulphonylurea-responsive. Herein, we present the successful transfer from insulin therapy to sulphonylureas following the identification of an ABCC8 mutation in a patient with NDM and his affected mother who was on insulin therapy for 8 years.

Case: A 7-month-old male presented with hyperglycemia. He was born at term by caesarean delivery to non-consanguineous parents after an uneventful gestation with a birth weight of 2750 gr. His mother and two aunts had diabetes and were on insulin therapy. On physical examination, his length was 66 cm (-1.56 SD) and weight was 8.4 kg (0.1 SD). Other physical findings were normal. In laboratory examination, blood glucose was 304 mg/dL, insulin: 1.9 μU/mL, C-peptide: 0.38 ng/mL, and hemoglobin A1c (HbA1c) was 8.4%. In urine analysis, he had (+++) glycosuria and mild ketonuria. He had no acidosis in blood gas analysis, and anti-glutamic acid decarboxylase antibodies were negative. Normoglycemia was achieved by insulin therapy. Molecular genetic analysis identified a heterozygous missense mutation, p.E208K (c.622G>A) in exon 5 of ABCC8 gene. The patient’s mother was heterozygous for the same mutation. A trial of sulphonylurea therapy in the patient and his mother with monogenic diabetes due to a heterozygous ABCC8 gene.

Key words: Monogenic diabetes, sulphonylurea, ABCC8 gene

Neonatal diabetes mellitus (NDM) which can be transient or permanent is a rare form of monogenic diabetes which usually presents in the first 6 months of life. Mutations in the KATP channel genes (ABCC8 and KCNJ11) are the most common cause of NDM. NDM due to ABCC8 and KCNJ11 mutations can be sulphonylurea-responsive. Herein, we present the successful transfer from insulin therapy to sulphonylureas following the identification of an ABCC8 mutation in a patient with NDM and his affected mother who was on insulin therapy for 8 years.

Case: A 7-month-old male presented with hyperglycemia. He was born at term by caesarean delivery to non-consanguineous parents after an uneventful gestation with a birth weight of 2750 gr. His mother and two aunts had diabetes and were on insulin therapy. On physical examination, his length was 66 cm (-1.56 SD) and weight was 8.4 kg (0.1 SD). Other physical findings were normal. In laboratory examination, blood glucose was 304 mg/dL, insulin: 1.9 μU/mL, C-peptide: 0.38 ng/mL, and hemoglobin A1c (HbA1c) was 8.4%. In urine analysis, he had (+++) glycosuria and mild ketonuria. He had no acidosis in blood gas analysis, and anti-glutamic acid decarboxylase antibodies were negative. Normoglycemia was achieved by insulin therapy. Molecular genetic analysis identified a heterozygous missense mutation, p.E208K (c.622G>A) in exon 5 of ABCC8 gene. The patient’s mother was heterozygous for the same mutation. A trial of sulphonylurea therapy in the patient and his mother with monogenic diabetes due to a heterozygous ABCC8 gene.

Key words: Monogenic diabetes, sulphonylurea, ABCC8 gene